Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18390139 | 0.83 | GAA (0.40) | GAANAAAEPHX2ALDH1A1MAPK1 | |
| SCHEMBL20353490 | 0.81 | GAA (0.38) | GAANAAAEPHX2ALDH1A1MAPK1 | |
| SCHEMBL20328130 | 0.79 | SMN1; SMN2 (0.46) | GAANAAAEPHX2ALDH1A1LMNA | |
| SCHEMBL20349548 | 0.79 | HRH3 (0.50) | GAANAAAEPHX2ALDH1A1TSHR | |
| SCHEMBL20382010 | 0.77 | EPHX2 (0.40) | GAANAAAEPHX2ALDH1A1MAPK1 | |
| SCHEMBL18390123 | 0.75 | POLB (0.58) | EPHX2ALDH1A1LMNARETTSHR | |
| SCHEMBL21476231 | 0.69 | — | — | |
| SCHEMBL23054218 | 0.68 | SMN1; SMN2 (0.58) | GAAALDH1A1LMNATSHR | |
| SCHEMBL26465575 | 0.66 | MAPT (0.37) | GAAALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL24109561 | 0.66 | TP53 (0.47) | GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127373-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127373-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | GAA 2839/4885NAAA 4476/4885EPHX2 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.